{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:45:57Z","timestamp":1781887557875,"version":"3.54.5"},"reference-count":33,"publisher":"American Psychiatric Association Publishing","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1176\/appi.ajp.162.5.954","type":"journal-article","created":{"date-parts":[[2005,4,30]],"date-time":"2005-04-30T01:27:58Z","timestamp":1114824478000},"page":"954-962","source":"Crossref","is-referenced-by-count":105,"title":["A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain"],"prefix":"10.1176","volume":"162","author":[{"given":"David C.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara B.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina P.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Cather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl M.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Eden","family":"Evins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Freudenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1625CACBJBFD","doi-asserted-by":"crossref","unstructured":"Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553\u2013564","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"R1625CACGFEDG","doi-asserted-by":"crossref","unstructured":"Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN: Olanzapine versus haloperidol: acute phase results of the International Double-Blind Olanzapine Trial. Eur Neuropsychopharmacol 1997; 7:125\u2013137","DOI":"10.1016\/S0924-977X(96)00392-6"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Baptista T, Beaulieu S: Body weight gain, insulin, and leptin in olanzapine-treated patients. J Clin Psychiatry 2001; 62:902\u2013904","DOI":"10.4088\/JCP.v62n1111b"},{"key":"R1625CACHGCGI","doi-asserted-by":"crossref","unstructured":"Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767\u2013770","DOI":"10.4088\/JCP.v60n1109"},{"key":"R1625CACCDJDJ","doi-asserted-by":"crossref","unstructured":"Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358\u2013363","DOI":"10.4088\/JCP.v60n0602"},{"key":"R1625CACFFFGI","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686\u20131696","DOI":"10.1176\/ajp.156.11.1686"},{"key":"R1625CACBFEHC","doi-asserted-by":"crossref","unstructured":"Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B: Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999; 19:273\u2013275","DOI":"10.1097\/00004714-199906000-00014"},{"key":"R1625CACGEGJD","doi-asserted-by":"crossref","unstructured":"Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101:277\u2013288","DOI":"10.1016\/S0165-1781(01)00234-7"},{"key":"R1625CACIDCGJ","doi-asserted-by":"crossref","unstructured":"Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54:565\u2013567","DOI":"10.1176\/appi.ps.54.4.565"},{"key":"R1625CACDFGCE","doi-asserted-by":"crossref","unstructured":"Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63:1121\u20131128","DOI":"10.4088\/JCP.v63n1206"},{"key":"R1625CACDCEJD","doi-asserted-by":"crossref","unstructured":"Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A: Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:297\u2013302","DOI":"10.1176\/appi.ajp.160.2.297"},{"key":"R1625CACCEDEE","doi-asserted-by":"crossref","unstructured":"Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A: Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159:1058\u20131060","DOI":"10.1176\/appi.ajp.159.6.1058"},{"key":"R1625CACJABFH","doi-asserted-by":"crossref","unstructured":"Glazer G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001; 161:1814\u20131824","DOI":"10.1001\/archinte.161.15.1814"},{"key":"R1625CACBDHFI","doi-asserted-by":"crossref","unstructured":"Finer N: Present and future pharmacological approaches. Br Med Bull 1997; 52:409\u2013432","DOI":"10.1093\/oxfordjournals.bmb.a011620"},{"key":"R1625CACFIGJD","doi-asserted-by":"crossref","unstructured":"Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum M: Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991; 50:330\u2013337","DOI":"10.1038\/clpt.1991.144"},{"key":"R1625CACEBCBF","doi-asserted-by":"crossref","unstructured":"Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286:1331\u20131339","DOI":"10.1001\/jama.286.11.1331"},{"key":"R1625CACHJBFB","doi-asserted-by":"crossref","unstructured":"Spitzer RL, Williams JBW, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624\u2013629","DOI":"10.1001\/archpsyc.1992.01820080032005"},{"key":"R1625CACHBEDC","unstructured":"Lohman TG: Exercise training and body composition in childhood. Can J Sport Sci 1992; 17:284\u2013287"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Jensen MD: Research techniques for body composition assessment. J Am Diet Assoc 1992; 92:454\u2013460","DOI":"10.1016\/S0002-8223(21)00651-9"},{"key":"R1625CACHEABF","doi-asserted-by":"crossref","unstructured":"Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54:254\u2013260","DOI":"10.1210\/jcem-54-2-254"},{"key":"R1625CACJHJGH","doi-asserted-by":"crossref","unstructured":"Durnin JV, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974; 32:77\u201397","DOI":"10.1079\/BJN19740060"},{"key":"R1625CACDIHDH","unstructured":"Thompson FE, Byers T: Dietary assessment resource manual. J Nutr 1994; 124(11 suppl):2245S-2317S"},{"key":"R1625CACHJCED","doi-asserted-by":"crossref","unstructured":"Kay SR, Singh MM: The positive-negative distinction in drug-free schizophrenic patients: stability, response to neuroleptics, and prognostic significance. Arch Gen Psychiatry 1989; 46:711\u2013718","DOI":"10.1001\/archpsyc.1989.01810080041005"},{"key":"R1625CACHHJCI","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23:99\u2013110","DOI":"10.1016\/0165-1781(88)90038-8"},{"key":"R1625CACBGFIB","doi-asserted-by":"crossref","unstructured":"Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766\u2013771","DOI":"10.1001\/archpsyc.1976.01770060086012"},{"key":"R1625CACDHFDA","unstructured":"Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, Kane JM: The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 1989; 25:222\u2013226"},{"key":"R1625CACDIJAE","doi-asserted-by":"crossref","unstructured":"Munetz MR, Benjamin S: How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39:1172\u20131177","DOI":"10.1176\/ps.39.11.1172"},{"key":"R1625CACFABAE","doi-asserted-by":"crossref","unstructured":"McNamara J, Schaefer E: Automated enzymatic standardized lipid analyses for plasma lipoprotein fractions. Clin Chim Acta 1987; 166:1\u20138","DOI":"10.1016\/0009-8981(87)90188-4"},{"key":"R1625CACEGICH","doi-asserted-by":"crossref","unstructured":"Warnick G, Benderson J, Albers J: Dextran sulfate-Mg2+ precipitation procedure for quantization of high-density-lipoprotein cholesterol. Clin Chem 1982; 28:1379\u20131388","DOI":"10.1093\/clinchem\/28.6.1379"},{"key":"R1625CACFCHFG","doi-asserted-by":"crossref","unstructured":"Friedewald W, Levy R, Fredrickson D: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499\u2013502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"R1625CACIGAEC","doi-asserted-by":"crossref","unstructured":"Nathan DM: Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. Clin Chem 1981; 27:1261\u20131263","DOI":"10.1093\/clinchem\/27.7.1261"},{"key":"R1625CACGJCFA","doi-asserted-by":"crossref","unstructured":"Reynolds GP, Zhang ZJ, Zhang XB: Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160:677\u2013679","DOI":"10.1176\/appi.ajp.160.4.677"},{"key":"R1625CACJGDHD","doi-asserted-by":"crossref","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ: Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002; 161:263\u2013270","DOI":"10.1007\/s00213-002-1016-3"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.5.954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T23:31:41Z","timestamp":1722382301000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.5.954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5,1]]}},"alternative-id":["10.1176\/appi.ajp.162.5.954"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.162.5.954","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}